What can be used to help prevent cardiomyopathy from anthracyclines in certain patients?

What can be used to help prevent cardiomyopathy from anthracyclines in certain patients?

• A. Carboplatin
• B. Dexrazoxane
• C. Filgrastim
• D. Cyclophosphamide

Answer: (B)

Dexrazoxane is utilized as a cardioprotective agent in patients receiving anthracycline chemotherapy, such as doxorubicin. Anthracyclines are well-known for their effectiveness in treating various cancers, but they can also induce cardiotoxicity, leading to conditions like cardiomyopathy. Dexrazoxane works by chelating iron and thereby reducing the oxidative stress that contributes to cardiac damage during anthracycline administration. Its mechanism involves preventing the formation of free radicals that can cause damage to cardiac myocytes, effectively mitigating the risk of developing heart-related side effects from the chemotherapy. This protective effect allows clinicians to use anthracyclines at potentially effective doses while minimizing the risk of long-term heart complications. The use of dexrazoxane is particularly recommended in patients with risk factors for cardiomyopathy, ensuring that they can still receive the necessary anticancer treatments without exposing them to significant cardiac risks.

Dexrazoxane is utilized as a cardioprotective agent in patients receiving anthracycline chemotherapy, such as doxorubicin. Anthracyclines are well-known for their effectiveness in treating various cancers, but they can also induce cardiotoxicity, leading to conditions like cardiomyopathy. Dexrazoxane works by chelating iron and thereby reducing the oxidative stress that contributes to cardiac damage during anthracycline administration.

Its mechanism involves preventing the formation of free radicals that can cause damage to cardiac myocytes, effectively mitigating the risk of developing heart-related side effects from the chemotherapy. This protective effect allows clinicians to use anthracyclines at potentially effective doses while minimizing the risk of long-term heart complications. The use of dexrazoxane is particularly recommended in patients with risk factors for cardiomyopathy, ensuring that they can still receive the necessary anticancer treatments without exposing them to significant cardiac risks.